CNA-3103

N/A

Report date: 2023/02/02 09:59:11

Base Information

Drug NameCNA-3103
Drug Alias NameCNA-3103
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionLeucine-rich repeat-containing G-protein coupled receptor 5 antagonists
TargetsLeucine-rich repeat-containing G-protein coupled receptor 5
Therapy Area/IndicationsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCarina Biotech Pty Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCarina Biotech Pty Ltd
Inactive CompaniesN/A
Active IndicationsColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A